Archive for February, 2012
When collecting and analyzing flow cytometry data, analysis consistency and quality control are essential in ensuring the validity of data within an experiment and among experiments carried out over time.
Quality control issues arise when there is variability in how experiments are carried out at the bench. We will tackle issues relating to data acquisition in a future post. In this post, we’ll discuss analysis-related quality concerns and introduce you to several Cytobank functionalities that are geared towards addressing these.
Where do issues surrounding quality control and analysis consistency arise?
- Multi-center endeavors to collect and analyze data
- Heads of labs who want to maintain consistency in analysis and presentation as scientists flux in and out of the lab
- Companies interested in a unified analysis and presentation style
- All scientists aiming to achieve reproducibility
You are probably familiar with our main server located at http://www.cytobank.org, but did you know that we offer hosted versions of Cytobank? With a hosted model, an individual lab or company has a server reserved for their exclusive use. The primary advantages of having your own hosted Cytobank include: 1) Premium Functionality, 2) Dedicated Computing Resources, 3) Access Control and Usage Monitoring, and 4) Premium Support and Quality Assurance. An additional perk is that you choose a name for the hosted Cytobank that shows up in the address (mylabname.cytobank.org, where ‘mylabname’ is a chosen name of your lab or group).
To help you consider if a hosted solution is right for you, here are some details about these advantages:
Having a hosted Cytobank means that you will stay current with cutting edge flow cytometry analysis techniques. Our hosted servers offer premium analysis functionality, such as SPADE and Dose Response Analysis. These tools are not available on the main Cytobank server (www.cytobank.org) and include implementations unique to Cytobank.
Welcome to Cytobank User Stories, a series featuring interviews with Cytobank users on their research, scientific vision, and use of flow cytometry.
This time we interview June Myklebust, Ph.D., a project leader in Erland Smeland’s lab at Oslo University Hospital and former postdoctoral fellow in the Levy Lab at Stanford. June’s recent publications include her contributions to studies on B-cell signaling networks in lymphoma and her work on bone morphogenetic proteins in B cell suppression.
Send us feedback and let us know who you’d like to hear from (including yourself)!
|What are you excited about in science? What is your scientific vision?|
|New discoveries that change our current biological models or change our view of what can be done in terms of therapeutic options. My scientific goal is to make discoveries from which patients can benefit. One of the challenges in cancer therapy today is to understand the molecular mechanisms for how patients develop fatal drug resistance. In the era of personalized medicine, development of in vitro assays with predictive power for drug-responsiveness, which then can guide the choice of therapy, would also be highly beneficial. I believe the ability to detect tumor cell heterogeneity will be crucial to address these issues, and therefore platforms for large-scale single cell measurements likely will be tiebreakers.|